Celemics, Inc.
Research Celemics, Inc. (331920.KQ) on Bullrun: market cap KRW 114.16B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker331920.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryMedical Devices
- CurrencyKRW
- Market capKRW 114.16B
- Financial periodQ2 2026
- RevenueKRW 1.38B
- Net income-KRW 5.23B
- Free cash flow-KRW 1.07B
- Gross margin39.4%
Valuation Snapshot
latest market cap is KRW 114.16B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 114.16B | n/a | n/a | n/a |
Dividend history
About Celemics, Inc.
Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Celemics, Inc.'s market cap?
Celemics, Inc.'s market capitalization is KRW 114.16B.
What does Celemics, Inc. do?
Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services.